Neoanthem Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 09-11-2024
- Paid Up Capital ₹ 1.50 M
as on 09-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 214.00 Cr
as on 09-11-2024
- Revenue %
(FY 2023)
- Net Worth -155.01%
(FY 2023)
- Total Assets 3551.69%
(FY 2023)
About Neoanthem Lifesciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹214.00 Cr.
K Chandrappa, Ganesh Sambasivam, and Ajay Bhardwaj serve as directors at the Company.
- CIN/LLPIN
U24239KA2020PTC136337
- Company No.
136337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jul 2020
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore Rural, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Neoanthem Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Sambasivam  | Director | 22-Jul-2020 | Current |
| K Chandrappa | Director | 22-Jul-2020 | Current |
| Ajay Bhardwaj | Director | 22-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Neoanthem Lifesciences.
Neoanthem Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 155.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Neoanthem Lifesciences?
In 2023, Neoanthem Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anthem Biosciences Private LimitedActive 18 years 6 monthsK Chandrappa, Ganesh Sambasivam and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Jun 2022 | ₹214.00 Cr | Open |
How Many Employees Work at Neoanthem Lifesciences?
Neoanthem Lifesciences has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neoanthem Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neoanthem Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
